From The Economic Times · Reuters · · 1m
US stocks drop as FDA rejects lung cancer drug approval
Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab.
In brief
Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab. US FDA declined to approve Summit Therapeutics' lung cancer drug ivonescimab, causing shares to drop 14%. Originally reported by The Economic Times.
FDA rejects lung cancer drug
US Food and Drug Administration declined to approve Summit Therapeutics' experimental lung cancer drug ivonescimab.
Shares drop 14%
Summit Therapeutics shares fell 14% at $12.16 in morning trading after FDA decision.
Drug study results
Late-stage study showed no statistically significant overall survival benefit for ivonescimab.
Regional patient outcomes
Follow-up data showed greater survival benefit in Chinese patients than North American and European patients.
FDA's regulatory impact
FDA decision sets meaningful regulatory precedent for lung cancer drug class with implications for Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
Drug mechanism
Ivonescimab targets proteins PD-1 and VEGF to help tumors evade immune system and spread.
Investor reaction
Investors await first-line trial data comparing ivonescimab against Merck's Keytruda for lung cancer treatment.
The key point
US FDA declined to approve Summit Therapeutics' lung cancer drug ivonescimab, causing shares to drop 14%.
Read the TL;DR — this story on one card.
